Core Viewpoint - Adial Pharmaceuticals, Inc. will implement a 1-for-25 reverse stock split to comply with Nasdaq's minimum bid price requirement and enhance its capital markets profile [1][3][4] Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from approximately 27.8 million to about 1.1 million, while maintaining the ownership percentage of each shareholder [2] - The reverse stock split will take effect on February 5, 2026, at 11:59 p.m. Eastern Time, with trading on a split-adjusted basis starting February 6, 2026 [1][2] - There will be no change to the total number of authorized shares as per the Company's Certificate of Incorporation [2] Group 2: Strategic Intentions - The reverse stock split aims to bring the Company into compliance with Nasdaq's minimum bid price requirement of at least $1.00 per share [3] - The action is expected to make the bid price more attractive to a wider range of institutional and retail investors [3][4] - The Company remains optimistic about its future and is focused on advancing its lead product, AD04, for the treatment of Alcohol Use Disorder [4][5] Group 3: Company Overview - Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for addiction and related disorders [5] - The lead investigational drug, AD04, is a genetically targeted serotonin-3 receptor antagonist aimed at treating Alcohol Use Disorder in heavy drinking patients [5] - The Company plans to conduct a new Phase 3 clinical trial program for AD04, which has shown promising results in reducing drinking without significant safety concerns [5]

Core Insights - Acurx Pharmaceuticals, Inc. (ACXP) has shown strong year-to-date performance compared to its Medical sector peers, returning 14.9% against the sector average of 5.4% [4] - The Zacks Rank for Acurx Pharmaceuticals is 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] - Over the past 90 days, the consensus estimate for ACXP's full-year earnings has increased by 22.7%, reflecting improved analyst sentiment [4] Company Performance - Acurx Pharmaceuticals is part of the Medical group, which includes 934 companies and ranks 5 in the Zacks Sector Rank [2] - In the Medical - Biomedical and Genetics industry, which consists of 455 companies, Acurx ranks 105, slightly underperforming the industry average return of 15.5% [6] - Adial Pharmaceuticals, Inc. (ADIL) is another Medical stock that has outperformed the sector, returning 16% year-to-date and also holding a Zacks Rank of 2 (Buy) [5] Analyst Sentiment - The Zacks Consensus Estimate for Adial Pharmaceuticals' current year EPS has increased by 31.6% over the past three months, indicating strong analyst confidence [5] - Investors are encouraged to monitor both Acurx Pharmaceuticals and Adial Pharmaceuticals for their continued solid performance in the Medical sector [7]

Upgrades Summary - Morgan Stanley upgraded Celsius Holdings (CELH) to Overweight from Equal Weight with a price target of $70, up from $61, citing a return to growth and expected reacceleration in topline growth due to easier comparisons from December through early June [2] - UBS upgraded FIS (FIS) to Buy from Neutral with an unchanged price target of $82, believing the risk/reward profile has improved as shares are down 20% year-to-date [2] - Oppenheimer upgraded Semtech (SMTC) to Outperform from Perform with a price target of $81, following positive management meetings and a bullish outlook on growth opportunities in data center artificial intelligence [2] - BofA upgraded Freeport-McMoRan (FCX) to Buy from Neutral with an unchanged price target of $42, expressing increased confidence in the current valuation despite risks associated with the halted Grasberg copper/gold mine in Indonesia [2] - Maxim upgraded Adial Pharmaceuticals (ADIL) to Buy from Hold with a price target of $1.50, reflecting a more bullish stance on the company [2]

Core Insights - Adial Pharmaceuticals achieved significant milestones in 2024, receiving positive feedback from the FDA on its 505(b)(2) bridging strategy and initiating clinical supply manufacturing for its upcoming Phase 3 trial [3] - The completion of the pharmacokinetics (PK) study for AD04, an investigational drug for Alcohol Use Disorder (AUD), confirmed the FDA's bridging requirements and supported the planned micro-dosing regimen for future trials [3] - The company strengthened its regulatory strategy by partnering with Boudicca Dx to develop a companion diagnostic genetic test for AD04, which is crucial for FDA discussions [3] Business Developments - The appointment of Vinay Shah as Chief Financial Officer was announced, bringing over 25 years of experience in the pharmaceutical and healthcare sectors [4] - Adial secured several foundational patents to enhance its intellectual property portfolio, including new patents for genetic-based approaches to treating AUD and opioid-related disorders [4][5][6][7] Financial Performance - As of December 31, 2024, cash and cash equivalents were $3.8 million, an increase from $2.8 million in 2023, expected to fund operations into the second half of 2025 [13] - Research and development expenses rose by approximately $1.9 million (155%) in 2024, primarily due to increased clinical trial expenses and manufacturing costs [13] - The net loss for 2024 was $13.2 million, compared to a net loss of $5.1 million in 2023, driven by non-cash charges and increased R&D spending [13]